Evaluating a new treatment approach for Malaria Vivax in Peru
Health Care Provider Use of Plasmodium Vivax Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru
This study is testing a new way to treat Malaria Vivax in Peru using two medications to see if it helps healthcare providers manage the disease better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 6 Months and up |
| Sex | All |
| Sponsor | Medicines for Malaria Venture Academic / other |
| Locations | 1 site (Nauta, Loreto) |
| Trial ID | NCT05361486 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the operational feasibility of a revised treatment algorithm for Malaria Vivax in Peru, utilizing Tafenoquine and Primaquine following semi-quantitative G6PD testing. It involves training healthcare providers on the new algorithm, patient counseling, and follow-up visits to ensure proper implementation. The study will be conducted across various health facilities in the Loreto Region, focusing on enhancing the management of P. vivax malaria cases. The findings are intended to inform potential policy changes and improve malaria treatment strategies in the region.
Who should consider this trial
Good fit: Ideal candidates include patients aged 6 months and older with a confirmed P. vivax infection receiving treatment at participating health facilities.
Not a fit: Patients with signs of severe infection or those who are pregnant or lactating with contraindications to both Primaquine and Tafenoquine may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer treatment options for patients with Malaria Vivax.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving malaria treatment outcomes, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria Health Care Providers: • All HCPs working in the selected facilities who are involved in the management of vivax patients. Inclusion criteria patients: * All patients aged 6 months onward, who have a confirmed P. vivax infection and who are treated in a study Health Facilities * Pregnant and lactating women, who have a contra-indication to both Primaquine and Tafenoquine, but for whom correct case management will be evaluated as part of the primary endpoints. * Patients providing informed consent and/or informed assent Exclusion criteria patients: • Patients with signs of severe infection
Where this trial is running
Nauta, Loreto
- Nauta Nucleo- Base — Nauta, Loreto, Peru (Recruiting)
Study contacts
- Principal investigator: Elmer Alejandro Llanos Cuentas, MD, PhD — Universidad Peruana Cayetano Heredia (UPCH)
- Study coordinator: Thy Do, PhD
- Email: dot@mmv.org
- Phone: +4179 515 94 05
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.